Quest Diagnostics Incorporated - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on May 20, 2026. Quest Diagnostics Incorporated (DGX) is a Delaware corporation with principal executive offices in Secaucus, NJ.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections: All 11 nominees were elected for terms expiring at the 2027 Annual Meeting. Notable "Against" votes included Vicky B. Gregg (10,232,574), Timothy M. Ring (11,994,424), and Gary M. Pfeiffer (7,716,970).
- Executive Compensation: The advisory resolution to approve executive officer compensation was approved with 86,869,738 votes "For" and 7,152,448 votes "Against".
- Independent Auditor: The ratification of PricewaterhouseCoopers as the independent registered public accounting firm for 2026 was approved with 97,340,034 votes "For" and 5,809,995 votes "Against".
- Stockholder Proposal: A proposal regarding an independent board chairman was not approved, receiving 23,999,636 votes "For" and 69,792,819 votes "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific reasons for the significant "Against" votes cast for directors Vicky B. Gregg and Timothy M. Ring.
- Review the 2026 Proxy Statement for details on the executive compensation package that was approved.
- Confirm the rationale behind the rejection of the stockholder proposal for an independent board chairman.
- Check subsequent filings for any financial updates or strategic changes resulting from the meeting outcomes.